Drugs / PVX108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05621317 | Feb 2023 → Nov 2025 overdue | anaphylaxis, food allergy | Aravax Pty Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PVX108 | “PVX108 comprises a mixture of peptides that represent sequences from peanut allergens” NCT05621317 ↗ |
| Modality | Peptide | “mixture of peptides that represent sequences from peanut allergens” NCT05621317 ↗ |
| Route | Other | “intradermal (ID) doses” NCT05621317 ↗ |